Cervical Dystonia Market size was valued at USD 230.3 million in 2024 and is anticipated to surpass USD 548.5 million by 2037, registering a CAGR of 7.5% during the forecast timeline i.e. 2025-2037. In 2025, the industry size of cervical dystonia is evaluated at USD 247.5 million.
The cervical dystonia market is gaining traction owing to advances in new neuroimaging techniques, genetic research, and neurotoxin therapies. For instance, in February 2024, Philips and Synthetic MR formed an alliance to enhance the diagnosis of neurological diseases in medical diagnostics. They strive to do so through advanced quantitative methods of brain imaging. In addition, precision medicine, where treatment is tailored to the genetic individuality of a person, is now making room for even more effective management strategies. For instance, in August 2023, BostonGene and NEC Corporation announced the formation of BostonGene Japan Inc. This Tokyo-based JV will advance precision medicine and significantly enhance patient outcomes.
Furthermore, botulinum toxin injections, a minimally invasive procedure are experiencing increased demand, thus making symptom management options more accessible. In addition, the emphasis is given to holistic care hence, integrated treatment with physiotherapy and psychiatric supports the patient. Moreover, advanced diagnostic techniques and patient awareness are propelling cervical dystonia treatment globally. For instance, in August 2021, Sense Neuro Diagnostics announced that the U.S. Army Medical Research and Development Command (USAMRDC) Combat Casualty Care Research Program has selected the company to receive USD 2.43 million from the U.S. Department of Defense. This funding is to advance the development of sensing technology to diagnose and monitor traumatic brain injury (TBI) in a field environment.
Growth Drivers
Challenges
Base Year |
2024 |
Forecast Year |
2025-2037 |
CAGR |
7.5% |
Base Year Market Size (2024) |
USD 230.3 million |
Forecast Year Market Size (2037) |
USD 548.5 million |
Regional Scope |
|
End user (Hospitals, Research Institutes, Long-term Care Facilities)
The hospital segment is likely to capture cervical dystonia market share of over 50.2% by 2037. primarily due to the facilities that can avail full-fledged care and specialized treatments. Advanced diagnostic tools are now available in hospitals, including neuroimaging, treatments such as botulinum toxin injections, physical therapy, and surgery. For instance, in September 2024, Allergan Aesthetics, an AbbVie company announced BOTOX Cosmetics is now approved in China to treat masseter muscle prominence. Hospitals continue to be the main site of care for most patients who require a multidisciplinary approach to treating the neurological and psychosocial aspects of the condition.
Treatment (Oral Therapy, Intravenous, Surgery, Others)
The oral therapy segment is anticipated to dominate the cervical dystonia market by 2037. It is primarily due to the accessibility and consequently effectiveness for symptomatic management of the disease. The oral drugs administered are mostly of the type of anticholinergics and muscle relaxants, given primarily to relax spasms of muscles and soothe pain due to which it is easy to treat the patients. For instance, in October 2024, AbbVie and Aliada Therapeutics announced a definitive agreement under which AbbVie will acquire Aliada for developing therapies using a novel blood-brain barrier (BBB). These therapies are usually used in addition to other treatments. Oral therapy will still hold its market share because of increased demand for non-invasive patient-friendly treatments.
Our in-depth analysis of the global cervical dystonia market includes the following segments:
End user |
|
Treatment |
|
Drug Type |
|
North America Market Statistics
North America cervical dystonia market is estimated to capture revenue share of over 50.3% by 2037, due to the growing unmet health-care needs. Moreover, a steep increase in the need for advanced medical centers, growing global cases of dystonia, and an increase in the incidence rate of other neurological disorders further propels the market growth. In addition, the prevalence of musculoskeletal conditions varies by age and diagnosis, which furthers the need for better and efficient patient outcomes.
The U.S. cervical dystonia market is experiencing significant growth attributable to the consistent research and development programs going across the country. For instance, in June 2024, Mayo Clinic researchers, and collaborators from all over the world, have set up the Pick's Disease International Consortium to explore a specific MAPT gene variant called MAPT H2, which codes for the tau protein and acts as a disease driver. The researchers were studying the link between the gene and disease risk, age at onset, and duration of Pick's disease.
In Canada, the cervical dystonia market is flourishing due to strong government support and initiatives. For instance, in May 2024, DiagnaMed introduced CERVAI, Brain Health AI in Canada. This AI solution estimates an individual's brain age and provides their brain health score. As part of its announcements in mid-January, the Ontario government committed over three years USD 60 million to support the Ontario Brain Institute in its mission to accelerate solutions to improving brain health. A further USD 5 million will go towards launching the Centre for Analytics - an initiative that supports neuroanalytical skills and AI models.
Asia Pacific Market Analysis
The cervical dystonia market in Asia Pacific is gaining traction and is expected to witness lucrative growth during the forecast timeline i.e. 2025-2037. The healthcare sector is expanding dramatically in this region due to the growing demand for better healthcare services, large government investments to upgrade healthcare infrastructure, and the growth of the medical tourism sector. This will propel the market throughout the projection period for the market.
The China market is growing significantly with the rise in infrastructure developments and equipping them with modern amenities & technologies. For instance, in November 2021, a new Center for Brain Imaging was established by NYU Shanghai and East China Normal University, its sister university. The center, located on the North Zhongshan Road Campus of ECNU, will focus on brain imaging initiatives that will help us better understand how children's brains and intelligence develop.
The India cervical dystonia market is expanding remarkably. This growth is attributed to the presence of tech-giants, who are constantly innovating in technologies that helps in early detection and treatment of abnormalities. For instance, in December 2024, The Indian Institute of Technology, Madras was the world's first scientific institution to publish the most detailed 3D high-resolution photographs of the fetal brain. Improvements in the current fetal imaging technologies for early detection and treatment of developmental abnormalities are the principal uses of producing such high-resolution images of the brain.
The cervical dystonia market is revolutionizing due to the presence of strong tech giants and pharmaceuticals who are collaboratively working to innovate and develop the effortless techniques. Such innovations help the market evolve in delivering better patient outcome. For instance, in June 2022, Amneal Pharmaceuticals, Inc. launched LYVISPAH, an oral granules specialty product for the treatment of spasticity associated with multiple sclerosis and other spinal cord conditions.
Here's the list of some key players:
Author Credits: Radhika Pawar
Copyright © 2025 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?